Patents by Inventor Naoka Hironiwa
Naoka Hironiwa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240158482Abstract: An objective of the present invention is to provide methods for promoting antigen uptake into cells by antigen-binding molecules, methods for increasing the number of times of antigen binding by one antigen-binding molecule, methods for promoting reduction of the antigen concentration in plasma by administering antigen-binding molecules, and methods for improving the plasma retention of an antigen-binding molecule, as well as antigen-binding molecules that allow enhanced antigen uptake into cells, antigen-binding molecules having an increased number of times of antigen binding, antigen-binding molecules that can promote reduction of the antigen concentration in plasma when administered, antigen-binding molecules with improved plasma retention, pharmaceutical compositions comprising the above antigen-binding molecules, and methods for producing them. The present inventors revealed that the above objective can be achieved by using antigen-binding molecules that show calcium-dependent antigen-antibody reaction.Type: ApplicationFiled: December 20, 2023Publication date: May 16, 2024Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Tomoyuki Igawa, Shinya Ishii, Miho Funaki, Naoka Hironiwa, Atsuhiko Maeda, Junichi Nezu, Yoshinao Ruike, Takeshi Baba, Shun Shimizu
-
Publication number: 20240150476Abstract: The present invention relates to a polypeptide comprising an antigen binding domain and a carrying moiety having an inhibiting domain that inhibits the antigen binding activity of the antigen binding domain, and having a longer half-life than that of the antigen binding domain existing alone, methods for producing and screening for the polypeptide, a pharmaceutical composition comprising the polypeptide, methods for producing and screening for a single-domain antibody whose antigen binding activity is inhibited by associating with particular VL, VH or VHH, and a fusion polypeptide library including a single-domain antibody whose antigen binding activity is inhibited by associating with particular VL, VH or VHH.Type: ApplicationFiled: December 22, 2023Publication date: May 9, 2024Inventors: Tomoyuki IGAWA, Hiroyuki ISHIKAWA, Naoka HIRONIWA
-
Patent number: 11952422Abstract: Antigen-binding domains that are capable of binding to CD3 and CD137 but do not bind to CD3 and CD137 at the same time and methods of using the same are provided. Methods to obtain antigen binding domains which bind to two or more different antigen more efficiently are also provided.Type: GrantFiled: December 4, 2018Date of Patent: April 9, 2024Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Shun Shimizu, Shu Wen Samantha Ho, Naoka Hironiwa, Mika Sakurai, Taro Miyazaki, Tomoyuki Igawa
-
Patent number: 11932697Abstract: The present invention relates to a polypeptide comprising an antigen binding domain and a carrying moiety having an inhibiting domain that inhibits the antigen binding activity of the antigen binding domain, and having a longer half-life than that of the antigen binding domain existing alone, methods for producing and screening for the polypeptide, a pharmaceutical composition comprising the polypeptide, methods for producing and screening for a single-domain antibody whose antigen binding activity is inhibited by associating with particular VL, VH or VHH, and a fusion polypeptide library including a single-domain antibody whose antigen binding activity is inhibited by associating with particular VL, VH or VHH.Type: GrantFiled: September 17, 2021Date of Patent: March 19, 2024Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Tomoyuki Igawa, Hiroyuki Ishikawa, Naoka Hironiwa
-
Patent number: 11891434Abstract: An objective of the present invention is to provide methods for promoting antigen uptake into cells by antigen-binding molecules, methods for increasing the number of times of antigen binding by one antigen-binding molecule, methods for promoting reduction of the antigen concentration in plasma by administering antigen-binding molecules, and methods for improving the plasma retention of an antigen-binding molecule, as well as antigen-binding molecules that allow enhanced antigen uptake into cells, antigen-binding molecules having an increased number of times of antigen binding, antigen-binding molecules that can promote reduction of the antigen concentration in plasma when administered, antigen-binding molecules with improved plasma retention, pharmaceutical compositions comprising the above antigen-binding molecules, and methods for producing them. The present inventors revealed that the above objective can be achieved by using antigen-binding molecules that show calcium-dependent antigen-antibody reaction.Type: GrantFiled: May 24, 2018Date of Patent: February 6, 2024Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Tomoyuki Igawa, Shinya Ishii, Miho Funaki, Naoka Hironiwa, Atsuhiko Maeda, Junichi Nezu, Yoshinao Ruike, Takeshi Baba, Shun Shimizu
-
Publication number: 20240026000Abstract: The present inventors have successfully prepared an antigen-binding molecule comprising an antibody variable region that has binding activity against a molecule expressed on the surface of a T cell and a molecule expressed on the surface of any other immunocyte, but does not bind to these molecules at the same time. The present invention allows the preparation of an antigen-binding molecule capable of circumventing adverse reactions that may be caused by the cross-linking of T cells to other immunocytes, and provides an antigen-binding molecule suitable as a drug.Type: ApplicationFiled: June 30, 2023Publication date: January 25, 2024Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Tomoyuki Igawa, Shojiro Kadono, Naoka Hironiwa, Mika Sakurai
-
Patent number: 11851476Abstract: It was found that association between CH1 and CL can be suppressed by substituting amino acids that exist on the interface between CH1 and CL with electrically-charged amino acids, and that formation of heterogeneous molecules is enabled more efficiently than by introducing knobs into holes mutations into CH3 domain.Type: GrantFiled: October 31, 2012Date of Patent: December 26, 2023Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Taichi Kuramochi, Meiri Kawazoe, Naoka Hironiwa, Tomoyuki Igawa
-
Patent number: 11820793Abstract: The present inventors discovered that by forming a large immune complex comprising antigens containing two or more antigenic binding units (epitopes) and two or more antigen-binding molecules (for example, antibodies), elimination from the plasma of the antigens containing two or more antigenic binding units can be accelerated. Moreover, they found that by using this characteristic and by further using antigen-binding molecules having an ion-dependent antigen-binding activity, elimination of the antigens can further be accelerated and the above problem can be solved.Type: GrantFiled: August 22, 2018Date of Patent: November 21, 2023Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Tomoyuki Igawa, Naoka Hironiwa
-
Patent number: 11739149Abstract: The present inventors have successfully prepared an antigen-binding molecule comprising an antibody variable region that has binding activity against a molecule expressed on the surface of a T cell and a molecule expressed on the surface of any other immunocyte, but does not bind to these molecules at the same time. The present invention allows the preparation of an antigen-binding molecule capable of circumventing adverse reactions that may be caused by the cross-linking of T cells to other immunocytes, and provides an antigen-binding molecule suitable as a drug.Type: GrantFiled: December 5, 2019Date of Patent: August 29, 2023Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Tomoyuki Igawa, Shojiro Kadono, Naoka Hironiwa, Mika Sakurai
-
Patent number: 11723976Abstract: In one non-limiting embodiment, the present disclosure relates to lyophilized formulations containing an IL-31 antagonist (for example, an anti-IL-31RA antibody) as an active ingredient, the lyophilized formulations further containing arginine and/or a salt thereof and sucrose and/or trehalose. In another non-limiting embodiment, the present disclosure relates to solution formulations containing an IL-31 antagonist as an active ingredient, the solution formulations further containing arginine and/or a salt thereof.Type: GrantFiled: January 12, 2022Date of Patent: August 15, 2023Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Daisuke Kameoka, Toru Yoshizawa, Megumi Numata, Hitoshi Sasaki, So Yamaguchi, Hiroko Murata, Naoka Hironiwa
-
Publication number: 20230151112Abstract: It was discovered that the use of an antigen-binding molecule having a cancer-specific antigen-binding domain, and a TNF superfamily-binding domain or a TNF receptor superfamily-binding domain enables agonist activity against a factor belonging to the TNF superfamily or the TNF receptor superfamily to be exhibited only in the presence of cancer-specific antigen-expressing cells, thus leading to activation of immune cells and thereby maintain anti-tumor activity while avoiding side effects such as hepatotoxicity. It was also discovered that concomitant use of the antigen-binding molecule with an antigen-binding molecule having a cancer-specific antigen-binding domain and a T cell receptor complex-binding domain can avoid side effects while increasing the anti-tumor activity.Type: ApplicationFiled: September 21, 2022Publication date: May 18, 2023Inventors: Tomoyuki IGAWA, Taro Miyazaki, Kenji Taniguchi, Naoka Hironiwa
-
Publication number: 20220401557Abstract: A multiple antigen-binding molecule fusion molecule containing a multiple antigen-binding molecule (?) having an immune cell antigen-binding region and a cancer antigen-binding region, a cancer tissue-specific protease-cleavable linker (?), and a masking molecule (?) containing a polypeptide having the amino acid sequence QDGNE, in which the multiple antigen-binding molecule (?) and the masking molecule (?) are linked via the cancer tissue-specific protease-cleavable linker (?).Type: ApplicationFiled: June 23, 2022Publication date: December 22, 2022Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Tomoyuki IGAWA, Naoka HIRONIWA, Hiroki KAWAUCHI
-
Patent number: 11485790Abstract: It was discovered that the use of an antigen-binding molecule having a cancer-specific antigen-binding domain, and a TNF superfamily-binding domain or a TNF receptor superfamily-binding domain enables agonist activity against a factor belonging to the TNF superfamily or the TNF receptor superfamily to be exhibited only in the presence of cancer-specific antigen-expressing cells, thus leading to activation of immune cells and thereby maintain anti-tumor activity while avoiding side effects such as hepatotoxicity. It was also discovered that concomitant use of the antigen-binding molecule with an antigen-binding molecule having a cancer-specific antigen-binding domain and a T cell receptor complex-binding domain can avoid side effects while increasing the anti-tumor activity.Type: GrantFiled: April 7, 2015Date of Patent: November 1, 2022Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Tomoyuki Igawa, Taro Miyazaki, Kenji Taniguchi, Naoka Hironiwa
-
Publication number: 20220315909Abstract: The present application relates to protease substrates, peptide sequences cleavable by a protease, polypeptides comprising a protease cleavage sequence and methods for production thereof, pharmaceutical compositions comprising a polypeptide comprising a protease cleavage sequence, and methods for releasing an antigen-binding domain or a ligand by the cleavage of a protease cleavage sequence included in a polypeptide.Type: ApplicationFiled: June 5, 2020Publication date: October 6, 2022Inventors: Mika SAKURAI, Tatsuya KAWA, Hitoshi KATADA, Naoka HIRONIWA
-
Publication number: 20220242934Abstract: The present inventors have successfully prepared an antibody Fc region dimer that has binding activity against each of an antigen and Fc?R, but does not bind to the antigen and the Fc?R at the same time, and a polypeptide comprising the Fc region dimer. The present invention enables the preparation of a multispecific binding polypeptide capable of avoiding an adverse reaction that may be caused by its binding to an antigen and Fc?R at the same time. Thus, the present invention provides a polypeptide suitable as a drug.Type: ApplicationFiled: September 24, 2021Publication date: August 4, 2022Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Tomoyuki Igawa, Naoka Hironiwa, Shojiro Kadono, Atsushi Matsuo, Taichi Kuramochi, Futa Mimoto
-
Patent number: 11400157Abstract: A multiple antigen-binding molecule fusion molecule containing a multiple antigen-binding molecule (?) having an immune cell antigen-binding region and a cancer antigen-binding region, a cancer tissue-specific protease-cleavable linker (?), and a masking molecule (?) containing a polypeptide having the amino acid sequence QDGNE (SEQ ID NO: 15), in which the multiple antigen-binding molecule (?) and the masking molecule (?) are linked via the cancer tissue-specific protease-cleavable linker (?).Type: GrantFiled: May 13, 2016Date of Patent: August 2, 2022Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Tomoyuki Igawa, Naoka Hironiwa, Hiroki Kawauchi
-
Publication number: 20220184210Abstract: In one non-limiting embodiment, the present disclosure relates to lyophilized formulations containing an IL-31 antagonist (for example, an anti-IL-31RA antibody) as an active ingredient, the lyophilized formulations further containing arginine and/or a salt thereof and sucrose and/or trehalose. In another non-limiting embodiment, the present disclosure relates to solution formulations containing an IL-31 antagonist as an active ingredient, the solution formulations further containing arginine and/or a salt thereof.Type: ApplicationFiled: March 4, 2022Publication date: June 16, 2022Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Daisuke Kameoka, Toru Yoshizawa, Megumi Numata, Hitoshi Sasaki, So Yamaguchi, Hiroko Murata, Naoka Hironiwa
-
Publication number: 20220187308Abstract: Disclosed is a library consisting essentially of a plurality of antigen-binding molecules differing in sequence from each other, wherein an antigen-binding domain in each of the antigen-binding molecules comprises at least one amino acid residue that changes the antigen-binding activity of the antigen-binding molecule depending on ion concentration conditions. Also disclosed are a composition comprising a plurality of polynucleotide molecules each encoding the antigen-binding molecules, a composition comprising a plurality of vectors each comprising the polynucleotide molecules, a method for selecting the antigen-binding molecules, a method for isolating the polynucleotide molecules, a method for producing the antigen-binding molecules, and a pharmaceutical composition comprising any of the antigen-binding molecules.Type: ApplicationFiled: December 22, 2021Publication date: June 16, 2022Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Tomoyuki IGAWA, Shinya ISHII, Miho FUNAKI, Naoka HIRONIWA, Shun SHIMIZU
-
Publication number: 20220125921Abstract: In one non-limiting embodiment, the present disclosure relates to lyophilized formulations containing an IL-31 antagonist (for example, an anti-IL-31RA antibody) as an active ingredient, the lyophilized formulations further containing arginine and/or a salt thereof and sucrose and/or trehalose. In another non-limiting embodiment, the present disclosure relates to solution formulations containing an IL-31 antagonist as an active ingredient, the solution formulations further containing arginine and/or a salt thereof.Type: ApplicationFiled: January 12, 2022Publication date: April 28, 2022Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Daisuke Kameoka, Toru Yoshizawa, Megumi Numata, Hitoshi Sasaki, So Yamaguchi, Hiroko Murata, Naoka Hironiwa
-
Publication number: 20220073632Abstract: The present invention relates to a polypeptide comprising an antigen binding domain and a carrying moiety having an inhibiting domain that inhibits the antigen binding activity of the antigen binding domain, and having a longer half-life than that of the antigen binding domain existing alone, methods for producing and screening for the polypeptide, a pharmaceutical composition comprising the polypeptide, methods for producing and screening for a single-domain antibody whose antigen binding activity is inhibited by associating with particular VL, VH or VHH, and a fusion polypeptide library including a single-domain antibody whose antigen binding activity is inhibited by associating with particular VL, VH or VHH.Type: ApplicationFiled: September 17, 2021Publication date: March 10, 2022Inventors: Tomoyuki IGAWA, Hiroyuki ISHIKAWA, Naoka HIRONIWA